Inhatarget Therapeutics SRL
5.2 FTEInhatarget Therapeutics reported total assets of €2.16m at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Jun 2026), with 5.2 full-time equivalents.
By total assets for 2025, Inhatarget Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Inhatarget Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -59 % Total assets -52 % Headcount (avg FTE) -13 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Inhatarget Therapeutics's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −921,288 € | ||||
| Equity | €1.57m | ||||
| Cash | 669,909 € | ||||
| EBITDA | −145,585 € | ||||
| Total assets | €2.16m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jun 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 01 Jul 2024
- Year ended 31 Dec 2022filed on 27 Jun 2023
- Year ended 31 Dec 2021filed on 22 Jun 2022
Inhatarget Therapeutics's financial analysis
- Solvency72.7%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Inhatarget Therapeutics
13 active director(s) in the register.
and 7 more
Inhatarget Therapeutics's shareholders and holdings →Inhatarget Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0732.994.752
- VAT number
- BE0732994752
- Peppol
- Registered · 0208:0732994752 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Aug 2019
- Registered office
- 6041 Charleroi
- Size
- Micro · 5.2 FTE
- Latest accounts
- 2025 · filed on 24 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Inhatarget Therapeutics (SRL) has been based in Charleroi since 2019, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 921,288 € and equity of €1.57m; its revenue is not published. With 5.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 72.7%, above the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Inhatarget Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Protea Biopharma NV Research and experimental development on natural sciences and engineering Asse · balance sheet €1.30m
- Novobiom Research and experimental development on natural sciences and engineering Liège · balance sheet €3.92m
- Stam Agro Research and experimental development on natural sciences and engineering Dendermonde · balance sheet €1.86m
- Abaxys Therapeutics Research and experimental development on natural sciences and engineering Villers-la-Ville · balance sheet €1.31m
- Celyad Oncology Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €4.03m
- Aneurotech Research and experimental development on natural sciences and engineering Alken · balance sheet €2.91m
- Dendrogenix Research and experimental development on natural sciences and engineering Liège · balance sheet €5.28m
- Dokter Frankie Nobels Research and experimental development on natural sciences and engineering Dendermonde · balance sheet €1.87m
Frequently asked questions about Inhatarget Therapeutics
What is the revenue of Inhatarget Therapeutics?
Inhatarget Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Inhatarget Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0732994752 for Inhatarget Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0732.994.752.
Where is the registered office of Inhatarget Therapeutics?
According to the CBE register, the registered office of Inhatarget Therapeutics is in 6041 Charleroi.
What is the equity of Inhatarget Therapeutics?
At the close of the 2025 financial year, the equity of Inhatarget Therapeutics amounts to 1,568,763 €, a solvency of 72.7% of total assets.
How many people work at Inhatarget Therapeutics?
5.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Inhatarget Therapeutics?
The register lists 13 active mandates at Inhatarget Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Inhatarget Therapeutics within its sector?
By total assets for 2025, Inhatarget Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Inhatarget Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →